News & Events
Disc Medicine Announces $90 Million Series B Financing to Advance Portfolio of Clinical-Stage Therapies for Hematologic Diseases
Proceeds will be used to advance multiple programs in Disc’s hematology pipeline into phase 2 development Financing led by OrbiMed and includes new investors Arix Bioscience, Janus Henderson Investors, 5AM Ventures, Rock Springs Capital and others CAMBRIDGE, Mass.
More News
Disc Medicine to Present Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2025 American Society of Nephrology (ASN) Kidney Week
WATERTOWN, Mass., Oct. 17, 2025 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and...
read more
Disc Medicine Announces Receipt of FDA Commissioner’s National Priority Voucher (CNPV) for Bitopertin in Erythropoietic Protoporphyria (EPP)
Disc is seeking accelerated approval of bitopertin for patients aged 12 years and older with EPP The CNPV program is designed to...
read more
Disc Medicine Announces Submission of New Drug Application (NDA) to US FDA for Accelerated Approval of Bitopertin for Patients with Erythropoietic Protoporphyria (EPP)
Disc is seeking accelerated approval and priority review of its NDA submission FDA decision to accept and file the NDA for review...
read more